Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Shuo Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7386-3446; OpenAlex author ID A5078145921. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 7 papers · 2020: 3 papers · 2021: 2 papers

Papers 15

  1. Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33410↗
  2. Comments on "Importance of Normalization of CA19-9 Levels After Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer". First author DOI 10.1097/sla.0000000000004538↗
  3. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Co-author DOI 10.1016/j.csbj.2020.11.018↗
  4. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. Co-author DOI 10.1038/s41388-020-01407-8↗
  5. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. First author DOI 10.3748/wjg.v26.i8.828↗
  6. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Co-author DOI 10.1002/cam4.1957↗
  7. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2430↗
  8. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2018.10.539↗
  9. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6941-4↗
  10. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.2147/cmar.s197911↗
  11. The Loss of SMAD4/DPC4 Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. Co-author DOI 10.7150/jca.30883↗
  12. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. Co-author DOI 10.7150/jca.32072↗
  13. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. First author DOI 10.1016/j.pan.2018.05.479↗
  14. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6727-8↗
  15. KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer. Co-author DOI 10.1093/abbs/gmv107↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huaxiang Xu · 14 shared papers, 2018–2021 · strength 1.31
  2. Xianjun Yu · 14 shared papers, 2018–2021 · strength 1.31
  3. Chuntao Wu · 13 shared papers, 2018–2021 · strength 1.14
  4. Heli Gao · 8 shared papers, 2018–2021 · strength 0.71
  5. Wenquan Wang · 8 shared papers, 2018–2021 · strength 0.71
  6. Liang Liu · 7 shared papers, 2018–2020 · strength 0.61
  7. Wuhu Zhang · 6 shared papers, 2019–2021 · strength 0.56
  8. Tianjiao Li · 6 shared papers, 2019–2021 · strength 0.56
  9. Liang Liu · 5 shared papers, 2019–2021 · strength 0.46
  10. Wen-Quan Wang · 5 shared papers, 2018–2020 · strength 0.43
  11. Quanxing Ni · 5 shared papers, 2018–2019 · strength 0.38
  12. Hao Li · 4 shared papers, 2019–2021 · strength 0.38
  13. He-Li Gao · 4 shared papers, 2018–2020 · strength 0.34
  14. Shi-Rong Zhang · 4 shared papers, 2018–2019 · strength 0.33
  15. Shirong Zhang · 4 shared papers, 2018–2019 · strength 0.31
  16. Wang Jiang · 3 shared papers, 2020–2021 · strength 0.31
  17. Xuan Han · 3 shared papers, 2020–2021 · strength 0.31
  18. Jin-Zhi Xu · 3 shared papers, 2018–2019 · strength 0.24
  19. Shuai-Shuai Xu · 2 shared papers, 2019–2020 · strength 0.18
  20. Liang Liu · 1 shared paper, 2021 · strength 0.17
  21. Jiang Long · 2 shared papers, 2018–2020 · strength 0.16
  22. Hao Li · 2 shared papers, 2018–2019 · strength 0.16
  23. Jin Xu · 2 shared papers, 2018–2019 · strength 0.16
  24. Zi-Hao Qi · 2 shared papers, 2018–2019 · strength 0.15
  25. Wei Jin · 2 shared papers, 2018–2019 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.